| 2025-04-23 | -0.29 % |
|
| 2025-04-21 | -0.19 % |
|
| 2025-04-17 | +2.01 % |
|
| 2025-04-16 | -2.46 % |
|
| 2025-04-15 | -0.99 % |
|
| 2025-04-14 | -0.01 % |
|
| 2025-04-11 | +2.1 % |
|
| 2025-04-10 | -5.32 % |
|
| 2025-04-09 | +3.75 % |
|
| 2025-04-07 | -0.36 % |
|
| 2025-04-04 | -5.7 % |
|
| 2025-04-03 | -0.24 % |
|
| 2025-04-02 | -0.6 % |
|
| 2025-04-01 | -2.94 % |
|
| 2025-03-31 | +0.59 % |
|
| 2025-03-27 | -0.58 % |
|
| 2025-03-26 | +0.27 % |
|
| 2025-03-25 | -4.81 % |
|
| 2025-03-24 | -0.86 % |
|
| 2025-03-21 | -1.71 % |
|
| 2025-03-19 | -0.74 % |
|
| 2025-03-18 | -0.07 % |
|
| 2025-03-17 | +0.23 % |
|
| 2025-03-13 | +1.46 % |
|
| 2025-03-11 | -0.53 % |
|
| 2025-03-07 | +0.69 % |
|
| 2025-03-06 | +0.87 % |
|
| 2025-03-05 | +0.68 % |
|
| 2025-02-27 | +1.34 % |
|
| 2025-02-26 | -2.24 % |
|
| 2025-02-25 | +0.18 % |
|
| 2025-02-21 | +2.08 % |
|
| 2025-02-19 | +2.77 % |
|
| 2025-02-14 | -1.67 % |
|
| 2025-02-13 | -1.46 % |
|
| 2025-02-12 | -1.01 % |
|
| 2025-02-07 | -0.87 % |
|
| 2025-02-05 | -1.18 % |
|
| 2025-02-04 | -9.07 % |
|
| 2025-02-03 | +0.98 % |
|
| 2025-01-30 | +0.68 % |
|
| 2025-01-29 | +0.85 % |
|
| 2025-01-27 | +2.5 % |
|
| 2025-01-23 | +0.99 % |
|
| 2025-01-15 | +0.44 % |
|
| 2025-01-13 | +1.74 % |
|
| 2025-01-10 | -0.6 % |
|
| 2025-01-07 | +1.3 % |
- Merck & Co. (MRK) stock rose 1.3% due in part to positive quarterly earnings results that exceeded expectations, alongside supportive ratings from multiple analysts, and an increase in dividend payouts, signaling confidence in the company's financial health.
- Merck & Co., Inc. (MRK) stock rose 1.3% amid various institutional investors adjusting their holdings and a generally positive outlook from analysts. The increase in stock price likely stems from the company's solid quarterly earnings report, which exceeded analyst expectations, and a raised dividend, signaling strong company performance and investor confidence.
- The article compares Bionomics and AstraZeneca, highlighting the strengths and weaknesses of each stock, while noting Merck & Co.'s collaboration with Bionomics. Merck & Co. (MRK) stock rose by 1.3% probably due to positive market sentiment driven by its collaboration with Bionomics, which is involved in developing innovative treatments, indicating potential for long-term growth.
|
| 2025-01-06 | +0.59 % |
|
| 2024-12-30 | -1.33 % |
|
| 2024-12-26 | +0.42 % |
|
| 2024-12-23 | +1.35 % |
|
| 2024-12-20 | -1.48 % |
|
| 2024-12-19 | +1.2 % |
|
| 2024-12-18 | -1.72 % |
|
| 2024-12-17 | |
|
| 2024-12-10 | -2.69 % |
|
| 2024-12-03 | +1.23 % |
|
| 2024-11-25 | +2 % |
|
| 2024-11-18 | +0.26 % |
|
| 2024-11-12 | -2.13 % |
|
| 2024-11-07 | +0.44 % |
|
| 2024-10-30 | +1.06 % |
|
| 2024-10-29 | -0.48 % |
|
| 2024-10-28 | +0.24 % |
|
| 2024-10-25 | -1.79 % |
|
